Hainan Shuangcheng Pharmaceut (002693) - Net Assets
Based on the latest financial reports, Hainan Shuangcheng Pharmaceut (002693) has net assets worth CN¥404.35 Million CNY (≈ $59.17 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥797.77 Million ≈ $116.74 Million USD) and total liabilities (CN¥393.42 Million ≈ $57.57 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hainan Shuangcheng Pharmaceut (002693) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥404.35 Million |
| % of Total Assets | 50.68% |
| Annual Growth Rate | 11.73% |
| 5-Year Change | -31.21% |
| 10-Year Change | -55.63% |
| Growth Volatility | 73.33 |
Hainan Shuangcheng Pharmaceut - Net Assets Trend (2009–2024)
This chart illustrates how Hainan Shuangcheng Pharmaceut's net assets have evolved over time, based on quarterly financial data. Also explore Hainan Shuangcheng Pharmaceut asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Hainan Shuangcheng Pharmaceut (2009–2024)
The table below shows the annual net assets of Hainan Shuangcheng Pharmaceut from 2009 to 2024. For live valuation and market cap data, see 002693 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥411.61 Million ≈ $60.23 Million |
-20.49% |
| 2023-12-31 | CN¥517.65 Million ≈ $75.75 Million |
-10.90% |
| 2022-12-31 | CN¥580.94 Million ≈ $85.01 Million |
+2.50% |
| 2021-12-31 | CN¥566.75 Million ≈ $82.93 Million |
-5.27% |
| 2020-12-31 | CN¥598.31 Million ≈ $87.55 Million |
-11.79% |
| 2019-12-31 | CN¥678.26 Million ≈ $99.25 Million |
+1.28% |
| 2018-12-31 | CN¥669.69 Million ≈ $98.00 Million |
-12.08% |
| 2017-12-31 | CN¥761.71 Million ≈ $111.46 Million |
+37.71% |
| 2016-12-31 | CN¥553.13 Million ≈ $80.94 Million |
-40.37% |
| 2015-12-31 | CN¥927.61 Million ≈ $135.74 Million |
+3.81% |
| 2014-12-31 | CN¥893.55 Million ≈ $130.75 Million |
+2.63% |
| 2013-12-31 | CN¥870.62 Million ≈ $127.40 Million |
+2.93% |
| 2012-12-31 | CN¥845.85 Million ≈ $123.77 Million |
+270.61% |
| 2011-12-31 | CN¥228.23 Million ≈ $33.40 Million |
+44.62% |
| 2010-12-31 | CN¥157.82 Million ≈ $23.09 Million |
+102.47% |
| 2009-12-31 | CN¥77.95 Million ≈ $11.41 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hainan Shuangcheng Pharmaceut's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 746.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥414.69 Million | 105.41% |
| Other Comprehensive Income | CN¥86.32 Million | 21.94% |
| Other Components | CN¥317.67 Million | 80.75% |
| Total Equity | CN¥393.41 Million | 100.00% |
Hainan Shuangcheng Pharmaceut Competitors by Market Cap
The table below lists competitors of Hainan Shuangcheng Pharmaceut ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Rutong Petro-Machinery
SHG:603036
|
$520.91 Million |
|
Electra Co Pr
TA:ECP
|
$521.28 Million |
|
Jana Small Finance Bank
NSE:JSFB
|
$521.52 Million |
|
Zhejiang Tiantai Xianghe Industrial Co Ltd
SHG:603500
|
$521.55 Million |
|
Anhui Xinbo Aluminum Co Ltd
SHE:003038
|
$520.64 Million |
|
Nanjing Railway New Technology Co.Ltd.
SHE:301016
|
$520.61 Million |
|
Hefei Gocom Information Technology Co Ltd
SHG:688367
|
$520.58 Million |
|
Beijing Haohan Data Technology Co. Ltd. A
SHG:688292
|
$520.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hainan Shuangcheng Pharmaceut's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 471,485,892 to 393,409,970, a change of -78,075,922 (-16.6%).
- Net loss of 78,304,732 reduced equity.
- Dividend payments of 7,191,873 reduced retained earnings.
- Other comprehensive income increased equity by 86,667,998.
- Other factors decreased equity by 79,247,315.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-78.30 Million | -19.9% |
| Dividends Paid | CN¥7.19 Million | -1.83% |
| Other Comprehensive Income | CN¥86.67 Million | +22.03% |
| Other Changes | CN¥-79.25 Million | -20.14% |
| Total Change | CN¥- | -16.56% |
Book Value vs Market Value Analysis
This analysis compares Hainan Shuangcheng Pharmaceut's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.99x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 33.61x to 8.99x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | CN¥0.26 | CN¥8.58 | x |
| 2010-12-31 | CN¥0.52 | CN¥8.58 | x |
| 2011-12-31 | CN¥0.75 | CN¥8.58 | x |
| 2012-12-31 | CN¥2.32 | CN¥8.58 | x |
| 2013-12-31 | CN¥2.17 | CN¥8.58 | x |
| 2014-12-31 | CN¥2.21 | CN¥8.58 | x |
| 2015-12-31 | CN¥2.29 | CN¥8.58 | x |
| 2016-12-31 | CN¥1.37 | CN¥8.58 | x |
| 2017-12-31 | CN¥1.87 | CN¥8.58 | x |
| 2018-12-31 | CN¥1.28 | CN¥8.58 | x |
| 2019-12-31 | CN¥1.33 | CN¥8.58 | x |
| 2020-12-31 | CN¥1.20 | CN¥8.58 | x |
| 2021-12-31 | CN¥1.19 | CN¥8.58 | x |
| 2022-12-31 | CN¥1.14 | CN¥8.58 | x |
| 2023-12-31 | CN¥1.12 | CN¥8.58 | x |
| 2024-12-31 | CN¥0.95 | CN¥8.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hainan Shuangcheng Pharmaceut utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -44.95%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.99x
- Recent ROE (-19.90%) is below the historical average (1.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 41.19% | 36.41% | 0.90x | 1.26x | CN¥24.31 Million |
| 2010 | 40.70% | 56.90% | 0.45x | 1.60x | CN¥48.45 Million |
| 2011 | 30.85% | 52.74% | 0.54x | 1.09x | CN¥47.59 Million |
| 2012 | 8.04% | 52.44% | 0.15x | 1.05x | CN¥-16.59 Million |
| 2013 | 7.67% | 44.63% | 0.16x | 1.05x | CN¥-20.29 Million |
| 2014 | 6.80% | 37.71% | 0.17x | 1.06x | CN¥-28.58 Million |
| 2015 | 5.68% | 22.81% | 0.15x | 1.67x | CN¥-40.08 Million |
| 2016 | -70.22% | -267.62% | 0.12x | 2.11x | CN¥-443.72 Million |
| 2017 | 1.07% | 2.56% | 0.18x | 2.33x | CN¥-52.82 Million |
| 2018 | -13.30% | -20.60% | 0.30x | 2.15x | CN¥-121.66 Million |
| 2019 | 4.51% | 7.11% | 0.36x | 1.74x | CN¥-29.97 Million |
| 2020 | -10.82% | -19.79% | 0.30x | 1.84x | CN¥-102.62 Million |
| 2021 | -4.22% | -6.35% | 0.37x | 1.77x | CN¥-68.51 Million |
| 2022 | 1.75% | 3.28% | 0.30x | 1.77x | CN¥-42.34 Million |
| 2023 | -10.76% | -21.51% | 0.29x | 1.70x | CN¥-97.89 Million |
| 2024 | -19.90% | -44.95% | 0.22x | 1.99x | CN¥-117.65 Million |
Industry Comparison
This section compares Hainan Shuangcheng Pharmaceut's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hainan Shuangcheng Pharmaceut (002693) | CN¥404.35 Million | 41.19% | 0.97x | $520.65 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. provides peptide, lyophilized, oncology, oral dosage, and other injection cartridge pharmaceutical products worldwide. The company offers thymalfasin, thymapentin, bortezmib, paclitaxel, somatostatin, pantoprazole, epifibatide, bivalirudin, liraglutide, and exenatide and sodium ferulate for injections, as well as vitamin B6. Hainan Shuangcheng Pharmace… Read more